Neuropsychology Review

, Volume 17, Issue 3, pp 347–361 | Cite as

Acute and Non-acute Effects of Cannabis on Brain Functioning and Neuropsychological Performance

  • Raul GonzalezEmail author


Cannabis has an ancient history of human use and is currently one of the most commonly used drugs worldwide. Understanding its impact on neurobehavioral functioning is of significant public health concern. In recent decades, substantial progress has been made in understanding the impact of cannabis use on neurobehavioral functioning. This has been fueled, in part, by characterization of an endocannabinoid signaling system in the brain through which cannabis exerts its psychoactive effects. Acute intoxication with cannabis causes marked changes in subjective mental status, brain functioning, and neuropsychological performance. Some of these changes are consistently detected and well characterized, yet others are not. Changes in brain functioning and neuropsychological performance are also reported after abstinence, but appear to be mild, circumscribed, and transient. On the other hand, functional neuroimaging often reveals subtle differences in the brain functioning of abstinent cannabis users compared with controls. The persistence and clinical significance of these differences, however, remains to be determined. Neuropsychological deficits and differences in brain functioning are most consistently observed only among frequent, heavy users, who are those most likely addicted to cannabis. The dire impact of drug addiction on a person’s life and everyday functioning suggests that the large number of individuals addicted to cannabis experience substantial negative effects from its use. This manuscript reviews the scientific literature on the aforementioned topics in detail, providing evidence for converging findings, and highlighting areas in need of further investigation.


Cannabis Cannabinoids Neuropsychology Cognitive effects THC Neuroimaging 


  1. Aasly, J., Storsaeter, O., Nilsen, G., Smevik, O., & Rinck, P. (1993). Minor structural brain changes in young drug abusers. A magnetic resonance study. Acta Neurologica Scandanivica, 87, 210–214.CrossRefGoogle Scholar
  2. Agurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., et al. (1986). Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacology Review, 38, 21–43.Google Scholar
  3. Amen, D. G., & Waugh, M. (1998). High resolution brain SPECT imaging of marijuana smokers with AD/HD. Journal of Psychoactive Drugs, 30, 209–214.PubMedGoogle Scholar
  4. Anthony, J. C., Warner, L. A., & Kessler, R. C. (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology, 2, 244–268.Google Scholar
  5. Bechara, A., Dolan, S., Denburg, N., Hindes, A., Anderson, S. W., & Nathan, P. E. (2001). Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia, 39, 376–389.PubMedGoogle Scholar
  6. Block, R. I., Erwin, W. J., Farinpour, R., & Braverman, K. (1998). Sedative, stimulant, and other subjective effects of marijuana: relationships to smoking techniques. Pharmacology Biochemistry and Behavior, 59, 405–412.Google Scholar
  7. Block, R. I., & Ghoneim, M. M. (1993). Effects of chronic marijuana use on human cognition. Psychopharmacology, 110, 219–228.PubMedGoogle Scholar
  8. Block, R. I., O’Leary, D. S., Ehrhardt, J. C., Augustinack, J. C., Ghoneim, M. M., Arndt, S., et al. (2000a). Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport, 11, 491–496.CrossRefGoogle Scholar
  9. Block, R. I., O’Leary, D. S., Hichwa, R. D., Augustinack, J. C., Boles Ponto, L. L., Ghoneim, M. M., et al. (2002). Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacology Biochemistry and Behavior, 72, 237–250.Google Scholar
  10. Block, R. I., O’Leary, D. S., Hichwa, R. D., Augustinack, J. C., Ponto, L. L. B., Ghoneim, M. M., et al. (2000b). Cerebellar hypoactivity in frequent marijuana users. Neuroreport, 11, 749–753.PubMedCrossRefGoogle Scholar
  11. Bolla, K. I., Brown, K., Eldreth, D., Tate, K., & Cadet, J. L. (2002). Dose-related neurocognitive effects of marijuana use. Neurology, 59, 1337–1343.PubMedGoogle Scholar
  12. Bolla, K. I., Eldreth, D. A., Matochik, J. A., & Cadet, J. L. (2005). Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage, 26, 480–492.PubMedGoogle Scholar
  13. Bornovalova, M. A., Daughters, S. B., Hernandez, G. D., Richards, J. B., & Lejuez, C. W. (2005). Differences in impulsivity and risk-taking propensity between primary users of crack cocaine and primary users of heroin in a residential substance-use program. Experimental and Clinical Psychopharmacology, 13, 311–318.PubMedGoogle Scholar
  14. Breivogel, C. S., Griffin, G., Di Marzo, V., & Martin, B. R. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology, 60, 155–163.PubMedGoogle Scholar
  15. Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry, 161, 1967–1977.PubMedGoogle Scholar
  16. Campbell, A. M., Evans, M., Thomson, J. L., & Williams, M. J. (1971). Cerebral atrophy in young cannabis smokers. Lancet, 2, 1219–1224.PubMedGoogle Scholar
  17. Carlin, A. S., & Trupin, E. W. (1977). The effect of long-term chronic marijuana use on neuropsychological functioning. International Journal of the Addictions, 12, 617–624.PubMedGoogle Scholar
  18. Chang, L., Yakupov, R., Cloak, C., & Ernst, T. (2006). Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain, 129, 1096–1112.PubMedGoogle Scholar
  19. Chevaleyre, V., & Castillo, P. E. (2004). Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron, 43, 871–881.PubMedGoogle Scholar
  20. Childers, S. R., Pacheco, M. A., Bennett, B. A., Edwards, T. A., Hampson, R. E., Mu, J., et al. (1993). Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochemical Society Symposia, 59, 27–50.Google Scholar
  21. Co, B. T., Goodwin, D. W., Gado, M., Mikhael, M., & Hill, S. Y. (1977). Absence of cerebral atrophy in chronic cannabis users. Evaluation by computerized transaxial tomography. Journal of the American Medical Association, 237, 1229–1230.PubMedGoogle Scholar
  22. Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., & Stinson, F. S. (2004). Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. Journal of the American Medical Association, 291, 2114–2121.PubMedGoogle Scholar
  23. Crippa, J. A., Lacerda, A. L., Amaro, E., Busatto, F. G., Zuardi, A. W., & Bressan, R. A. (2005). Brain effects of cannabis-neuroimaging findings. Revista Brasileira de Psiquiatria, 27, 70–78.PubMedGoogle Scholar
  24. Croft, R. J., Mackay, A. J., Mills, A. T. D., & Gruzelier, J. G. H. (2001). The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology, 153, 373–379.PubMedGoogle Scholar
  25. Crowley, T. J., Raymond, K. M., Mikulich-Gilbertson, S. K., Thompson, L. L., & Lejuez, C. W. (2006). A risk-taking “set” in a novel task among adolescents with serious conduct and substance problems. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 175–183.PubMedGoogle Scholar
  26. Davies, S. N., Pertwee, R. G., & Riedel, G. (2002). Functions of cannabinoid receptors in the hippocampus. Neuropharmacology, 42, 993–1007.PubMedGoogle Scholar
  27. Deif, A., El, S. A., & Fawzy, R. K. (1993). Neurological, psychiatric and C.T. evaluation of chronic cannabis smokers. Journal of the Medical Research Institute, 14, 151–160.Google Scholar
  28. De Petrocellis, L., Cascio, M. G., & Di Marzo, V. (2004). The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology, 141, 765–774.PubMedGoogle Scholar
  29. Devane, W. A., Dysarz, F. A., III, Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34, 605–613.PubMedGoogle Scholar
  30. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946–1949.PubMedGoogle Scholar
  31. Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., et al. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: Evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. Journal of Neurochemistry, 75, 2434–2444.PubMedGoogle Scholar
  32. Ehrenreich, H., Rinn, T., Kunert, H. J., Moeller, M. R., Poser, W., Schilling, L., et al. (1999). Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology, 142, 295–301.PubMedGoogle Scholar
  33. Eldreth, D. A., Matochik, J. A., Cadet, J. L., & Bolla, K. I. (2004). Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage, 23, 914–920.PubMedGoogle Scholar
  34. Ellis, G. M., Jr., Mann, M. A., Judson, B. A., Schramm, N. T., & Tashchian, A. (1985). Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clinical Pharmacology and Therapeutics, 38, 572–578.PubMedCrossRefGoogle Scholar
  35. ElSohly, M. A., Ross, S. A., Mehmedic, Z., Arafat, R., Yi, B., & Banahan, B. F. (2000). Potency trends of Delta(9)-THC and other cannabinoids in confiscated marijuana from 1980–1997. Journal of Forensic Sciences, 45, 24–30.PubMedGoogle Scholar
  36. ElSohly, M. A., & Slade, D. (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sciences, 78, 539–548.PubMedGoogle Scholar
  37. Eubanks, L. M., Rogers, C. J., Beuscher, A. E., Koob, G. F., Olson, A. J., Dickerson, T. J., et al. (2006). A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Molecular Pharmacology, 3, 773–777.Google Scholar
  38. European Monitoring Centre for Drugs and Drug Addiction. (2004). Annual Report 2004: The state of the drugs problem in the European Union and Norway Luxembourg: Office for Official Publications of the European Communities.Google Scholar
  39. Ferraro, D. P. (1980). Acute effects of marijuana on human memory and cognition. In R. C.Petersen (Ed.), Marijuana research findings: 1980. Washington D.C.: Department of Health and Human Services.Google Scholar
  40. Fillmore, M. T., & Rush, C. R. (2002). Impaired inhibitory control of behavior in chronic cocaine users. Drug and Alcohol Dependence, 66, 265–273.PubMedGoogle Scholar
  41. Fisk, J. E., Montgomery, C., Wareing, M., & Murphy, P. N. (2006). The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic? Human Psychopharmacology, 21, 355–366.PubMedGoogle Scholar
  42. Fletcher, J. M., Page, J. B., Francis, D. J., Copeland, K., Naus, M. J., Davis, C. M., et al. (1996). Cognitive correlates of long-term cannabis use in Costa Rican men. Archives of General Psychiatry, 53, 1051–1057.PubMedGoogle Scholar
  43. Fride, E., Foox, A., Rosenberg, E., Faigenboim, M., Cohen, V., Barda, L., et al. (2003). Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a “CB3” receptor. European Journal of Pharmacology, 461, 27–34.PubMedGoogle Scholar
  44. Fried, P. A., & Smith, A. M. (2001). A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicology and Teratology, 23, 1–11.PubMedGoogle Scholar
  45. Fried, P. A., Watkinson, B., & Gray, R. (2005). Neurocognitive consequences of marihuana—a comparison with pre-drug performance. Neurotoxicology and Teratology, 27, 231–239.PubMedGoogle Scholar
  46. Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry, 232, 54–61.PubMedGoogle Scholar
  47. Glass, M., Brotchie, J. M., & Maneuf, Y. P. (1997a). Modulation of neurotransmission by cannabinoids in the basal ganglia. Eureopean Journal of Neuroscience, 9, 199–203.PubMedGoogle Scholar
  48. Glass, M., Dragunow, M., & Faull, R. L. (1997b). Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 77, 299–318.PubMedGoogle Scholar
  49. Gonzalez, R., Bechara, A., & Martin, E. M. (2007). Executive functions among individuals with methamphetamine or alcohol as drugs of choice: Preliminary observations. Journal of Clininical and Experimental Neuropsychology, 29, 155–159.Google Scholar
  50. Gonzalez, R., Carey, C., & Grant, I. (2002). Nonacute (Residual) neuropsychological effects of cannabis use: A qualitative analysis and systematic review. Journal of Clinical Pharmacology, 42, 48S–57S.PubMedGoogle Scholar
  51. Gonzalez, S., Cebeira, M., & Fernandez-Ruiz, J. (2005). Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacology Biochemistry and Behavior, 81, 300–318.Google Scholar
  52. Gonzalez, R., Rippeth, J. D., Carey, C. L., Heaton, R. K., Moore, D. J., Schweinsburg, B. C., et al. (2004). Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug and Alcohol Dependence, 76, 181–190.PubMedGoogle Scholar
  53. Gouzoulis-Mayfrank, E., Daumann, J., Tuchtenhagen, F., Pelz, S., Becker, S., Kunert, H. J., et al. (2000). Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). Journal of Neurology, Neurosurgery and Psychiatry, 68, 719–725.Google Scholar
  54. Grant, I. & Cahn, B. R. (2005). Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Clinical Neuroscience Research, 5(2–4), 185–199.PubMedGoogle Scholar
  55. Grant, S., Contoreggi, C., & London, E. D. (2000). Drug abusers show impaired performance in a laboratory test of decision making. Neuropsychologia, 38, 1180–1187.PubMedGoogle Scholar
  56. Grant, I., Gonzalez, R., Carey, C. L., Natarajan, L., & Wolfson, T. (2003). Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. Journal of the International Neuropsychological Society, 9, 679–689.PubMedGoogle Scholar
  57. Grant, I., Rochford, J., Fleming, T., & Stunkard, A. (1973). A neuropsychological assessment of the effects of moderate marihuana use. Journal of Nervous & Mental Disease, 156, 278–280.CrossRefGoogle Scholar
  58. Green, B., Kavanagh, D., & Young, R. (2003). Being stoned: a review of self-reported cannabis effects. Drug and Alcohol Review, 22, 453–460.PubMedGoogle Scholar
  59. Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42, 327–360.PubMedGoogle Scholar
  60. Gruber, S. A., & Yurgelun-Todd, D. A. (2005). Neuroimaging of marijuana smokers during inhibitory processing: A pilot investigation. Brain Research, 23, 107–118.PubMedGoogle Scholar
  61. Grundy, R. I. (2002). The therapeutic potential of the cannabinoids in neuroprotection. Expert Opinions on Investigational Drugs, 11, 1365–1374.Google Scholar
  62. Guzman, M., Sanchez, C., & Galve-Roperh, I. (2001). Control of the cell survival/death decision by cannabinoids. Journal of Molecular Medicine, 78, 613–625.PubMedGoogle Scholar
  63. Hamil, W. L. (1996). Auditory learning and memory performance among veterans with a history of stimulant abuse. Dissertation Abstracts International: Section B: The Sciences & Engineering, 56, 5806.Google Scholar
  64. Hampson, A. J., Grimaldi, M., Lolic, M., Wink, D., Rosenthal, R., & Axelrod, J. (2000). Neuroprotective antioxidants from marijuana. Annals of the New York Academy of Sciences, 899, 274–282.PubMedCrossRefGoogle Scholar
  65. Hannerz, J., & Hindmarsh, T. (1983). Neurological and neuroradiological examination of chronic cannabis smokers. Annals of Neurology, 13, 207–210.PubMedGoogle Scholar
  66. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., et al. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 98, 3662–3665.PubMedGoogle Scholar
  67. Heishman, S. J., Stitzer, M. L., & Yingling, J. E. (1989). Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacology Biochemistry and Behavior, 34, 173–179.Google Scholar
  68. Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., et al. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences, 87, 1932–1936.Google Scholar
  69. Hermann, D., Sartorius, A., Welzel, H., Walter, S., Skopp, G., Ende, G., et al. (2007). Dorsolateral prefrontal cortex n-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biolgical Psychiatry, 61, 1281–1289.Google Scholar
  70. Herning, R. I., Hooker, W. D., & Jones, R. T. (1986). Tetrahydrocannabinol content and differences in marijuana smoking behavior. Psychopharmacology, 90, 160–162.PubMedGoogle Scholar
  71. Huestis, M. A., Mitchell, J. M., & Cone, E. J. (1996). Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. Journal of Analytical Toxicology, 20, 441–452.PubMedGoogle Scholar
  72. Iversen, L. L. (2000). The science of marijuana. New York: Oxford University Press.Google Scholar
  73. Jager, G., Kahn, R. S., Van Den, B. W., Van Ree, J. M., & Ramsey, N. F. (2006). Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology, 185, 358–368.PubMedGoogle Scholar
  74. Jager, G., Van Hell, H. H., De Win, M. M., Kahn, R. S., Van Den, B. W., Van Ree, J. M., et al. (2007). Effects of frequent cannabis use on hippocampal activity during an associative memory task. European Neuropsychopharmacology, 17, 289–297.PubMedGoogle Scholar
  75. Jiang, H. E., Li, X., Zhao, Y. X., Ferguson, D. K., Hueber, F., Bera, S., et al. (2006). A new insight into Cannabis sativa (Cannabaceae) utilization from 2500-year-old Yanghai Tombs, Xinjiang, China. Journal of Ethnopharmacology, 108, 414–422.PubMedGoogle Scholar
  76. Johnston, L. D., O’Malley, P. M., Bachman, J. G., & Schulenberg, J. E. (2006). Monitoring the future study. Washington, DC: NIDA.Google Scholar
  77. Kanayama, G., Rogowska, J., Pope, H. G., Gruber, S. A., & Yurgelun-Todd, D. A. (2004). Spatial working memory in heavy cannabis users: A functional magnetic resonance imaging study. Psychopharmacology, 176, 239–247.PubMedGoogle Scholar
  78. Kelleher, L. M., Stough, C., Sergejew, A. A., & Rolfe, T. (2004). The effects of cannabis on information-processing speed. Addictive Behaviors, 29, 1213–1219.PubMedGoogle Scholar
  79. Kirby, K. N., Petry, N. M., & Bickel, W. K. (1999). Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. Journal of Experimental Psychology-General, 128, 78–87.PubMedGoogle Scholar
  80. Kuehnle, J., Mendelson, J. H., Davis, K. R., & New, P. F. (1977). Computed tomographic examination of heavy marijuana smokers. Journal of the American Medical Association, 237, 1231–1232.PubMedGoogle Scholar
  81. Landfield, P. W., Cadwallader, L. B., & Vinsant, S. (1988). Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: Possible mediation by glucocorticoid systems. Brain Research, 443, 47–62.PubMedGoogle Scholar
  82. Lane, S. D., Cherek, D. R., Tcheremissine, O. V., Lieving, L. M., & Pietras, C. J. (2005). Acute marijuana effects on human risk taking. Neuropsychopharmacology, 30, 800–809.PubMedGoogle Scholar
  83. Lawston, J., Borella, A., Robinson, J. K., & Whitaker-Azmitia, P. M. (2000). Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Research, 877, 407–410.PubMedGoogle Scholar
  84. Leshner, A. I. (1997). Addiction is a brain disease, and it matters. Science, 278, 45–47PubMedGoogle Scholar
  85. Loeber, R. T. & Yurgelun-Todd, D. A. (1999). Human neuroimaging of acute and chronic marijuana use: Implications for frontocerebellar dysfunction. Human Psychopharmacology-Clinical and Experimental, 14, 291–304.Google Scholar
  86. Lundqvist, T., Jonsson, S., & Warkentin, S. (2001). Frontal lobe dysfunction in long-term cannabis users. Neurotoxicology and Teratology, 23, 437–443.PubMedGoogle Scholar
  87. Lyons, M. J., Bar, J. L., Panizzon, M. S., Toomey, R., Eisen, S., Xian, H., et al. (2004). Neuropsychological consequences of regular marijuana use: A twin study. Psychological Medicine, 34, 1239–1250.PubMedGoogle Scholar
  88. Madden, G. J., Petry, N. M., Badger, G. J., & Bickel, W. K. (1997). Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: Drug and monetary rewards. Experimental and Clinical Psychopharmacology, 5, 256–262.PubMedGoogle Scholar
  89. Maejima, T., Ohno-Shosaku, T., & Kano, M. (2001). Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neuroscience Research, 40, 205–210.PubMedGoogle Scholar
  90. Maldonado, R. (2002). Study of cannabinoid dependence in animals. Pharmacology & Therapeutics, 95, 153–164.Google Scholar
  91. Maldonado, R., Valverde, O., & Berrendero, F. (2006). Involvement of the endocannabinoid system in drug addiction. Trends in Neuroscience, 29, 225–232.Google Scholar
  92. Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., & Behl, C. (2002). Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1. Journal of Neurochemistry, 80, 448–456.PubMedGoogle Scholar
  93. Mathew, R. J., Tant, S., & Burger, C. (1986). Regional cerebral blood flow in marijuana smokers. British Journal of Addictions, 81, 567–571.Google Scholar
  94. Mathew, R. J., & Wilson, W. H. (1993). Acute changes in cerebral blood-flow after smoking marijuana. Life Sciences, 52, 757–767.PubMedGoogle Scholar
  95. Mathew, R. J., Wilson, W. H., Chiu, N. Y., Turkington, T. G., Degrado, T. R., & Coleman, R. E. (1999). Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatrica Scandinavica, 100, 67–75.PubMedGoogle Scholar
  96. Mathew, R. J., Wilson, W. H., Coleman, R. E., Turkington, T. G., & Degrado, T. R. (1997). Marijuana intoxication and brain activation in marijuana smokers. Life Sciences, 60, 2075–2089.PubMedGoogle Scholar
  97. Mathew, R. J., Wilson, W. H., Humphreys, D. F., Lowe, J. V., & Wiethe, K. E. (1992). Regional cerebral blood flow after marijuana smoking. Journal of Cerebral Blood Flow and Metabolism, 12, 750–758.PubMedGoogle Scholar
  98. Mathew, R. J., Wilson, W. H., & Tant, S. R. (1989). Acute changes in cerebral blood-flow associated with marijuana smoking. Acta Psychiatrica Scandinavica, 79, 118–128.PubMedGoogle Scholar
  99. Mathew, R. J., Wilson, W. H., Turkington, T. G., & Coleman, R. E. (1998). Cerebellar activity and disturbed time sense after THC. Brain Research, 797, 183–189.PubMedGoogle Scholar
  100. Mathew, R. J., Wilson, W. H., Turkington, T. G., Hawk, T. C., Coleman, R. E., DeGrado, T. R., et al. (2002). Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Research: Neuroimaging, 116, 173–185.PubMedGoogle Scholar
  101. Matochik, J. A., Eldreth, D. A., Cadet, J. L., & Bolla, K. I. (2005). Altered brain tissue composition in heavy marijuana users. Drug and Alcohol Dependence, 77, 23–30.PubMedGoogle Scholar
  102. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561–564.PubMedGoogle Scholar
  103. McAllister, S. D., & Glass, M. (2002). CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins, Leukotrienes and Essential Fatty Acids, 66, 161–171.Google Scholar
  104. McDonald, J., Schleifer, L., Richards, J. B., & de Wit, H. (2003). Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology, 28, 1356–1365.PubMedGoogle Scholar
  105. Mechoulam, R. (2002). Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukotrienes and Essential Fatty Acids, 66, 93–99.Google Scholar
  106. Mechoulam, R., Benshabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50, 83–90.PubMedGoogle Scholar
  107. Mechoulam, R., & Gaoni, Y. (1967). The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Letters, 12, 1109–1111.PubMedGoogle Scholar
  108. Mechoulam, R., & Hanus, L. (2000). A historical overview of chemical research on cannabinoids. Chemistry and Physics of Lipids, 108, 1–13.PubMedGoogle Scholar
  109. Mechoulam, R., Panikashvili, D., & Shohami, E. (2002). Cannabinoids and brain injury: therapeutic implications. Trends in Molecular Medicine, 8, 58–61.PubMedGoogle Scholar
  110. Medina, K. L., Schweinsburg, A. D., Cohen-Zion, M., Nagel, B. J., & Tapert, S. F. (2007). Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. Neurotoxicology and Teratology, 29, 141–152.PubMedGoogle Scholar
  111. Merlin, M. D. (2003). Archaeological evidence for the tradition of psychoactive plant use in the Old World. Economic Botany, 57, 295–323.Google Scholar
  112. Messinis, L., Kyprianidou, A., Malefaki, S., & Papathanasopoulos, P. (2006). Neuropsychological deficits in long-term frequent cannabis users. Neurology, 66, 737–739.PubMedGoogle Scholar
  113. Milton, N. G. (2002). Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neuroscience Letters, 332, 127–130.PubMedGoogle Scholar
  114. Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61–65.PubMedGoogle Scholar
  115. National Drug Intelligence Center (2005). National Drug Threat Assessment 2005 U.S. Department of Justice.Google Scholar
  116. O’Leary, D. S., Block, R. I., Flaum, M., Schultz, S. K., Boles Ponto, L. L., Watkins, G. L., et al. (2000). Acute marijuana effects on rCBF and cognition: A PET study. Neuroreport, 11, 3835–3841.PubMedGoogle Scholar
  117. O’Leary, D. S., Block, R. I., Koeppel, J. A., Flaum, M., Schultz, S. K., Andreasen, N. C., et al. (2002). Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology, 26, 802–816.PubMedGoogle Scholar
  118. O’Leary, D. S., Block, R. I., Turner, B. M., Koeppel, J., Magnotta, V. A., Ponto, L. B., et al. (2003). Marijuana alters the human cerebellar clock. Neuroreport, 14, 1145–1151.PubMedGoogle Scholar
  119. Onaivi, E. S., Ishiguro, H., Gong, J. P., Patel, S., Perchuk, A., Meozzi, P. A., et al. (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Annals of the New York Academy of Sciences, 1074, 514–536.PubMedGoogle Scholar
  120. Pertwee, R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and Therapeutics, 74, 129–180.PubMedGoogle Scholar
  121. Petry, N. M., Bickel, W. K., & Arnett, M. (1998). Shortened time horizons and insensitivity to future consequences in heroin addicts. Addiction, 93, 729–738.PubMedGoogle Scholar
  122. Pillay, S. S., Rogowska, J., Kanayama, G., Jon, D. I., Gruber, S., Simpson, N., et al. (2004). Neurophysiology of motor function following cannabis discontinuation in chronic cannabis smokers: An fMRI study. Drug and Alcohol Dependence, 76, 261–271.PubMedGoogle Scholar
  123. Pope, H. G. (2002). Cannabis, cognition, and residual confounding. Journal of the American Medical Association, 287, 1172–1174.PubMedGoogle Scholar
  124. Pope, H. G., Gruber, A. J., Hudson, J. I., Huestis, M. A., & Yurgelun-Todd, D. (2001). Neuropsychological performance in long-term cannabis users. Archives of General Psychiatry, 58, 909–915.PubMedGoogle Scholar
  125. Pope, H. G., Jr., Gruber, A. J., & Yurgelun-Todd, D. (1995). The residual neuropsychological effects of cannabis: the current status of research. Drug and Alcohol Dependence, 38, 25–34.PubMedGoogle Scholar
  126. Pope, H. G. Jr., & Yurgelun-Todd, D. (1996). The residual cognitive effects of heavy marijuana use in college students. Journal of the American Medical Association, 275, 521–527.PubMedGoogle Scholar
  127. Porter, A. C., Sauer, J. M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J. Q., et al. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Journal of Pharmacology and Experimental Therapeutics, 301, 1020–1024.PubMedGoogle Scholar
  128. Poulsen, H. A., & Sutherland, G. J. (2000). The potency of cannabis in New Zealand from 1976 to 1996. Science & Justice, 40, 171–176.CrossRefGoogle Scholar
  129. Quickfall, J., & Crockford, D. (2006). Brain neuroimaging in cannabis use: A review. Journal of Neuropsychiatry and Clinical Neurosciences, 18, 318–332.PubMedGoogle Scholar
  130. Ramaekers, J. G., Kauert, G., van Ruitenbeek, P., Theunissen, E. L., Schneider, E., & Moeller, M. R. (2006). High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology, 31, 2296–2303.PubMedGoogle Scholar
  131. Ramirez, B. G., Blazquez, C., Gomez del, P. T., Guzman, M., & de Ceballos, M. L. (2005). Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. Journal of Neuroscience, 25, 1904–1913.PubMedGoogle Scholar
  132. Ranganathan, M., & D’Souza, D. C. (2006). The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology, 188, 425–444.PubMedGoogle Scholar
  133. Rochford, J., Grant, I., & LaVigne, G. (1977). Medical students and drugs: Further neuropsychological and use pattern considerations. International Journal of the Addictions, 12, 1057–1065.PubMedGoogle Scholar
  134. Rodgers, J. (2000). Cognitive performance amongst recreational users of “ecstasy”. Psychopharmacology, 151, 19–24.PubMedGoogle Scholar
  135. Rojas, R., Riascos, R., Vargas, D., Cuellar, H., & Borne, J. (2005). Neuroimaging in drug and substance abuse part I: Cocaine, cannabis, and ecstasy. Topics in Magnetic Resonance Imaging, 16, 231–238.PubMedGoogle Scholar
  136. SAMHSA. (2005). Summary of Findings from the 2005 National Household Survey on Drug Abuse. Rockville, MD, Office of Applied Studies. Ref Type: Generic.Google Scholar
  137. Sarne, Y., & Keren, O. (2004). Are cannabinoid drugs neurotoxic or neuroprotective? Medical Hypotheses, 63, 187–192.PubMedGoogle Scholar
  138. Sarne, Y., & Mechoulam, R. (2005). Cannabinoids: Between neuroprotection and neurotoxicity. Current Drug Targets CNS and Neurological Disorders, 4, 677–684.PubMedGoogle Scholar
  139. Scallet, A. C., Uemura, E., Andrews, A., Ali, S. F., McMillan, D. E., Paule, M. G., et al. (1987). Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Research, 436, 193–198.PubMedGoogle Scholar
  140. Schweinsburg, A. D., Schweinsburg, B. C., Cheung, E. H., Brown, G. G., Brown, S. A., & Tapert, S. F. (2005). fMRI response to spatial working memory in adolescents with comorbid marijuana and alcohol use disorders. Drug and Alcohol Dependence, 79, 201–210.PubMedGoogle Scholar
  141. Sneider, J. T., Pope, H. G., Jr., Silveri, M. M., Simpson, N. S., Gruber, S. A., & Yurgelun-Todd, D. A. (2006). Altered regional blood volume in chronic cannabis smokers. Experimental and Clinical Psychopharmacology, 14, 422–428.PubMedGoogle Scholar
  142. Solowij, N. (1995). Do cognitive impairments recover following cessation of cannabis use? Life Sciences, 56, 2119–2126.PubMedGoogle Scholar
  143. Solowij, N. (1998). Cannabis and cognitive functioning. New York: Cambridge University Press.Google Scholar
  144. Solowij, N. (1999). Long-term effects of cannabis on the central nervous system. In H. Kalant, W. Corrigall, W. Hall, & R. Smart (Eds.), The health effects of cannabis (pp. 195–265). Toronto: Addiction Research Foundation.Google Scholar
  145. Solowij, N., Stephens, R. S., Roffman, R. A., Babor, T., Kadden, R., Miller, M., et al. (2002). Cognitive functioning of long-term heavy cannabis users seeking treatment. Journal of the American Medical Association, 287, 1123–1131.PubMedGoogle Scholar
  146. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., et al. (1995). 2-Arachidonoylgylcerol—A possible endogenous cannabinoid receptor-ligand in brain. Biochemical and Biophysical Research Communications, 215, 89–97.PubMedGoogle Scholar
  147. Tanda, G., & Goldberg, S. R. (2003). Cannabinoids: Reward, dependence, and underlying neurochemical mechanisms—A review of recent preclinical data. Psychopharmacology, 169, 115–134.PubMedGoogle Scholar
  148. Tunving, K., Thulin, S. O., Risberg, J., & Warkentin, S. (1986). Regional cerebral blood-flow in long-term heavy cannabis use. Psychiatry Research, 17, 15–21.PubMedGoogle Scholar
  149. Tzilos, G. K., Cintron, C. B., Wood, J. B., Simpson, N. S., Young, A. D., Pope, H. G. Jr., et al. (2005). Lack of hippocampal volume change in long-term heavy cannabis users. American Journal of Addictions, 14, 64–72.Google Scholar
  150. United Nations Office on Drugs and Crimes. (2004). World Drug Report United Nations Publications.Google Scholar
  151. Vanyukov, M. M., Tarter, R. E., Kirisci, L., Kirillova, G. P., Maher, B. S., & Clark, D. B. (2003). Liability to substance use disorders: 1. Common mechanisms and manifestations. Neuroscience and Biobehavioral Review, 27, 507–515.Google Scholar
  152. Verdejo-Garcia, A., Benbrook, A., Funderburk, F., David, P., Cadet, J. L., & Bolla, K. I. (2007). The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. Drug and Alcohol Dependence, 90, 2–11.PubMedGoogle Scholar
  153. Volkow, N. D., Gillespie, H., Mullani, N., Tancredi, L., Grant, C., Ivanovic, M., et al. (1991). Cerebellar metabolic-activation by delta-9-tetrahydro-cannabinol in human brain—A study with positron emission tomography and F-18 2-fluoro-2-deoxyglucose. Psychiatry Research-Neuroimaging, 40, 69–78.Google Scholar
  154. Volkow, N. D., Gillespie, H., Mullani, N., Tancredi, L., Grant, C., Valentine, A., et al. (1996). Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Research-Neuroimaging, 67, 29–38.Google Scholar
  155. Wachtel, S. R., ElSohly, M. A., Ross, S. A., Ambre, J., & de, W. H. (2002). Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology, 161, 331–339.PubMedGoogle Scholar
  156. Wert, R. C., & Raulin, M. L. (1986). The chronic cerebral effects of cannabis use. II. Psychological findings and conclusions. International Journal of Addictions, 21, 629–642.Google Scholar
  157. Whitlow, C. T., Liguori, A., Livengood, L. B., Hart, S. L., Mussat-Whitlow, B. J., Lamborn, C. M., et al. (2004). Long-term heavy marijuana users make costly decisions on a gambling task. Drug and Alcohol Dependence, 76, 107–111.PubMedGoogle Scholar
  158. Wiesbeck, G. A., & Taeschner, K. L. (1991). A cerebral computed tomography study of patients with drug-induced psychoses. European Archives of Psychiatry and Clininical Neuroscience, 241, 88–90.Google Scholar
  159. Wig, N. N., & Varma, V. K. (1977). Patterns of long-term heavy cannabis use in North India and its effects on cognitive functions: A preliminary report. Drug & Alcohol Dependence, 2, 211–219.Google Scholar
  160. Wilson, W., Mathew, R., Turkington, T., Hawk, T., Coleman, R. E., & Provenzale, J. (2000). Brain morphological changes and early marijuana use: A magnetic resonance and positron emission tomography study. Journal of Addictive Disease, 19, 1–22.Google Scholar
  161. Zuardi, A. W. (2006). History of cannabis as a medicine: A review. Revista Brasileira de Psiquiatria, 28, 153–157.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of Illinois, ChicagoChicagoUSA

Personalised recommendations